This finding provides supporting evidence for using [68Ga]Ga-P16-093 PET/CT in biopsy localization and guidance for local treatment. ![Figure][1] [1]: pending:yesJiarou WangLinlin LiRongxi WangZhien ZhouLin ZhuWeigang YanHank KungZhaohui Zhu...
This study was prospectively designed to evaluate the early dynamic organ distribution and tumor detection capability of [ 68 Ga]Ga-P16-093, which was compared with [ 68 Ga]Ga-PSMA-617 in the same group of recurrent prostate cancer patients.Twenty patients with recurrent prostate cancer were enr...
Results of in vitro binding studies, cell uptake, and retention (using PSMA-positive prostate carcinoma cells line, 22Rv1-FOLH1-oe) were comparable to that of [68Ga]Ga-P16-093 and [177Lu]Lu-PSMA-617, respectively. Specific cellular uptake was determined with or without the ...
18F-FDG PET/CT holds better clinical potential for evaluating UTUC and detecting lymph node metastasis compared to68Ga-PSMA-11 PET/CT, likely due to the relatively scant expression of FOLH1 in tumor neovascular endothelium while the abundant expression of GLUT1 in malignancy. Furthermore, the low...
Conclusions: [68Ga]Ga-P16-093 appears useful for pre-prostatectomy assessment of patients with intermediate- or high-risk prostate cancer to better define the regional location(s) of disease. In this initial assessment, PET-derived knowledge of regional PSMA expression would have modified surgical ...
[68Ga]Ga-P16-093This study was undertaken to evaluate radiation dosimetry for the prostate-specific membrane antigen targeted [ 68 Ga]Ga-P16-093 radiopharmaceutical, and to initially assess agent performance in positron emission tomography (PET) detection of the site of disease in prostate cancer ...
The SUVmax of tumor measured by 68Ga-P16-093 PET/CT had a moderate association with biopsy Gleason score (r = 0.462, P = 0.005) and prostate-specific antigen value (r = 0.491, P = 0.002), and significantly correlated with PSMA expression (r = 0.732, P < 0.001). Conclusions 68Ga-...
Kit-based preparation of [ 68 Ga]Ga-P16-093 (PSMA-093) using different commercial 68 Ge/ 68 Ga generatorsHaiyan Hong aGuochang Wang bKarl Ploessl dZhihao Zha dJie Zang bZhaohui Zhu bLin Zhu aHank F. Kung c d
Purpose This study was prospectively designed to evaluate the early dynamic organ distribution and tumor detection capability of [Ga-68]Ga-P16-093, which was compared with [Ga-68]Ga-PSMA-617 in the same group of recurrent prostate cancer patients. Methods Twenty patients with recurrent prostate ...
Previously, [ 68 Ga]Ga-P16-093, containing a Ga(III) chelator, N , N ′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine- N , N ′-diacetic acid (HBED-CC), displayed excellent PSMA-targeting properties and showed a high tumor uptake and retention useful for diagnosis in prostate ...